US Stock Futures Rise Ahead Of Manufacturing PMI

Pre-open movers US stock futures traded higher in early pre-market trade. The manufacturing PMI for September will be released at 9:45 a.m. ET. Futures for the Dow Jones Industrial Average climbed 54.5 points to 16,283.5, while the Standard & Poor's 500 index futures rose 5.75 points to 1,937.75. Futures for the Nasdaq 100 index surged 18 points to 4,285.25. A Peek Into Global Markets European markets were higher today, with the Spanish Ibex Index rising 0.23 percent, STOXX Europe 600 Index gaining 0.55 percent and German DAX 30 index surging 0.69 percent. French CAC 40 Index surged 0.66 percent and London's FTSE 100 Index rose 1.37 percent. In Asian markets, Hong Kong's Hang Seng Index fell 2.26 percent, China's Composite Index Index declined 2.19 percent and India's BSE Sensex gained 0.67 percent. Broker Recommendation Analysts at Nomura upgraded Carnival Corp CCL from Neutral to Buy and raised the price target from $53.00 to $62.00. Carnival shares fell 5.45 percent to close at $49.81 yesterday. Breaking news

• OncoGenex Pharmaceuticals Inc OGXI announced today initial results from the Phase 2 Rainier(TM) study evaluating apatorsen in combination with ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer. To read the full news, click here.
• Heron Therapeutics Inc HRTX today announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Heron's proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. To read the full news, click here.
• Questar Corporation STR today announced that its subsidiary, Wexpro Company, has entered into a joint venture to develop natural gas-producing properties in western Colorado's Piceance Basin. To read the full news, click here.
• Regenxbio Inc RGNX today announced the closing of its initial public offering of 7,245,000 shares of common stock at a public offering price of $22.00 per share, which includes 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. To read the full news, click here.